Recent Updates
Recently added Catalysts

DOS

Phase 2

Stomach Neoplasms | Small Molecules | Oncology |Sanofi|Trials Updated: Sep 21, 2012

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment44

FDA Designations

No designations recorded

DOS clinical trials

DOS · 1 trial · 1 indication

Phase 2 1
NCT00525005Docetaxel, Oxaliplatin and S-1 (DOS) for Advanced Gastric CancerStomach Neoplasms
COMPLETED44 Analytics
PHASE2COMPLETED
Docetaxel, Oxaliplatin and S-1 (DOS) for Advanced Gastric Cancer
Stomach NeoplasmsUnlock trial analytics

Study Endpoints

Primary Endpoints

overall response rate
2.5 years

Secondary Endpoints

safety, progression-free survival, and overall survival
2.5 years
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
DOS (Docetaxel, Oxaliplatin and S-1)EXPERIMENTALDocetaxel 52.5mg/m2 IV on D1 (diluted in 250 ml of normal saline over a 1 hour of each cycle before oxaliplatin) Oxaliplatin 105mg/m2 IV on D1 (diluted in 250 ml of 5% DW for 2 hours) S-1 80mg/m2/day on D1-14 (2 weeks of treatment followed by a 1-week rest period)

Interventions

NameTypeDescription
DOS (Docetaxel, Oxaliplatin and S-1)DRUGDocetaxel 52.5mg/m2 IV on D1 (diluted in 250 ml of normal saline over a 1 hour of each cycle before oxaliplatin) Oxaliplatin 105mg/m2 IV on D1 (diluted in 250 ml of 5% DW for 2 hours) S-1 80mg/m2/day on D1-14 (2 weeks of treatment followed by a 1-week rest period)
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 70 Years
SexALL
Healthy VolunteersNo
Study Sites2

Inclusion Criteria: * Histologically confirmed gastric adenocarcinoma, initially diagnosed or recurred * Unresectable, locally advanced or metastatic * At least one uni-dimensional measurable lesion by RECIST criteria * Age 18 to 70 years old * ECOG performance status ≤2 * Estimated life expectancy...

Countries:South Korea
Unlock Eligibility Criteria

Frequently asked questions about DOS

What is DOS (Docetaxel, Oxaliplatin and S-1)?

DOS is a three-drug combination regimen of docetaxel, oxaliplatin and S-1, also written as DOS (Docetaxel, Oxaliplatin and S-1). It is an investigational small molecule oncology regimen developed by Sanofi (ticker SNY) and studied in stomach neoplasms, also called gastric cancer. The combination has been evaluated in a Phase 2 trial.

What is DOS used for in stomach neoplasms?

DOS was studied for advanced gastric cancer, the condition listed as stomach neoplasms. The regimen combines docetaxel, oxaliplatin and S-1 and was tested in a Phase 2 trial of 44 participants with advanced gastric cancer in South Korea. It is investigational and not an approved therapy.

Who makes DOS?

Sanofi, which trades under the ticker SNY, is the developer of the DOS regimen. DOS stands for the combination of docetaxel, oxaliplatin and S-1, three small molecule agents given together. Sanofi sponsored the Phase 2 study of the regimen in advanced gastric cancer.

What phase is DOS in?

DOS is in Phase 2 development. The only listed trial of the regimen, NCT00525005, was a Phase 2 study titled Docetaxel, Oxaliplatin and S-1 (DOS) for Advanced Gastric Cancer. That trial is completed, and no active trials of DOS are currently listed.

What clinical trials is DOS in?

DOS has been studied in one clinical trial, NCT00525005, titled Docetaxel, Oxaliplatin and S-1 (DOS) for Advanced Gastric Cancer. It was a Phase 2, uncontrolled, non-randomized study that enrolled 44 participants aged 18 years and older in South Korea. The trial is completed.